{"disease":{"id":"symptom-withdrawal","name":"symptom withdrawal"},"drugs":{"marketed":[{"drug_id":"diazepam-2mg-encapsulated-tab","indication_name":"Symptomatic relief of acute alcohol withdrawal","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Diazepam 2Mg encapsulated Tab","company_name":"The University of Hong Kong","drug_phase":"marketed","molecular_target":"GABA-A receptor (allosteric modulator)","drug_class":"Benzodiazepine","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04939623","title":"Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"University of Calgary","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}